We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
- Authors
Ghia, Paolo; Pluta, Andrzej; Wach, Malgorzata; Lysak, Daniel; Kozak, Tomas; Simkovic, Martin; Kaplan, Polina; Kraychok, Iryna; Illes, Arpad; De La Serna, Javier; Dolan, Sean; Campbell, Phillip; Musuraca, Gerardo; Jacob, Abraham; Avery, Eric J.; Lee, Jae Hoon; Liang, Wei; Patel, Priti; Quah, Cheng; Jurczak, Wojciech
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2019, Vol 19, pS280
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2019.07.217